Calciphylaxis Market Size to Reach $2.8 billion by 2034

According to Straits Research the global calciphylaxis market size was valued at $1.4 billion in 2025 and is projected to grow from $1.5 billion in 2026 to $2.8 billion by 2034 at a CAGR of 8.0% during the forecast period 2026-2034.

The global calciphylaxis market is expected to witness steady growth due to increasing awareness of this rare disease, advancements in diagnostic techniques, and the development of improved treatment options. Calciphylaxis is a severe condition characterized by calcium deposits in small blood vessels, leading to painful skin ulcers and tissue damage. It is commonly associated with chronic kidney disease and requires early diagnosis and effective treatment to improve patient outcomes.

The calciphylaxis market is segmented based on type, diagnostics, treatment, end use, and region. Some of the insights provided in the report are highlighted below:

The non-uremic segment is expected to register a CAGR of 8.66% during the forecast period.
North America is expected to lead the market during the forecast period, owing to high burden of chronic kidney and severe renal diseases.
Favorable reimbursement framework for high-cost therapies supports higher treatment utilization in North America.
The US is expected to lead the North America market due to easy access to therapies such as sodium thiosulfate, advanced wound care, and hyperbaric oxygen therapy.

Straits Research adopts a rigorous 360° research approach that integrates both primary and secondary research methodologies. The report data is triangulated with a mix of market indicators, macroeconomic outlook, industry sources, and strategic briefings.

The report is designed to enable decision makers, such as CXOs, policymakers, investors, startups, and other related stakeholders, to understand the current and future scenario of the market.

North America dominates the global calciphylaxis market, supported by advanced healthcare infrastructure, greater awareness of rare diseases, strong research activities, and wider availability of specialized treatment options. Asia-Pacific is expected to register the fastest growth during the forecast period, driven by improving healthcare infrastructure, increasing awareness, expanding research initiatives, and better access to diagnostic and treatment services.